Seiichi Mawatari

17PUBLICATIONS
32CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseasesGastroenterology and hepatologyAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 09, 2026
Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy.

Takanori Suzuki, Kentaro Matsuura, Yuki Tahata

|Sep 18, 2025
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination.

Yuta Myojin, Hayato Hikita, Yuki Tahata

|May 31, 2025
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria.

Takashi Niizeki, Seiichi Mawatari, Michihiko Shibata

|Sep 07, 2023
Magnetic resonance imaging-based risk factors of hepatocellular carcinoma after direct-acting antiviral therapy: A multicenter observational study.

Shintaro Ichikawa, Utaroh Motosugi, Yoshiyuki Sawai

|Feb 22, 2023
A case of acute liver failure due to aggressive natural killer-cell leukemia with a rapid course.

Ai Toyodome, Seiichi Mawatari, Ohki Taniyama

|Dec 23, 2022
Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma.

Seiichi Mawatari, Tsutomu Tamai, Kotaro Kumagai

Pageof 3

Frequent Collaborators

3 joint publications

Hisamitsu Miyaaki

2 joint publications

Hiroshi Yatsuhashi

2 joint publications

Kentaro Matsuura

2 joint publications

Hitoshi Yoshiji